The Department of Genetic Eye Diseases and Rare Diseases (Consultation) is a newly established tertiary discipline in recent years. The current academic leader is Dr. Wu Jihong, Deputy Director of the Ophthalmology Department of our hospital, Executive Vice President of the Research Institute, and Doctoral Supervisor. She has been selected for the Shanghai Leading Talent Program, Shanghai Outstanding Academic Leader Program, and Shanghai Medical Leading Talent Program. She serves as Vice Chair of the Ophthalmology and Visual Science Committee of the Chinese Research Hospital Association, Vice Chair of the Ocular Genetic Disease Branch of the Chinese Genetics Society, and Executive Deputy Director of the Shanghai Key Laboratory of Visual Impairment and Reconstruction. She was the first in China to establish a specialized clinic for genetic eye diseases and has accumulated extensive experience in diagnosis and treatment. She has led nearly 20 provincial and ministerial-level or above projects, including key research and development program projects of the Ministry of Science and Technology, general projects of the National Natural Science Foundation of China, and major special projects of the Shanghai Municipal Science and Technology Commission. The research group is dedicated to precision diagnosis, gene therapy, pharmacotherapy, stem cell therapy, and next-generation genetic risk assessment for inherited eye diseases. 　　The discipline is committed to advancing simultaneously in clinical care, education, and research, and has achieved a series of breakthrough results. First, in terms of diagnosis and treatment, precision diagnostic methods and pathways for genetic eye diseases have been established, significantly improving the precision diagnosis rate. Through in-depth analysis of pathogenic genes and fundus lesions, traditional cognitive constraints have been broken, and precise interventions have been developed based on individual genetic differences and disease characteristics. An innovative personalized pharmacotherapy regimen for inherited retinal degeneration has been proposed, truly achieving "one person, one strategy, precision customization" in clinical treatment, tailoring a "treatment-specific code" for each patient, and achieving excellent clinical efficacy. At the same time, clinical trials of gene therapy, optogenetic therapy, and exosome therapy are actively being carried out. In terms of education, the department undertakes lecture delivery for visiting physicians and graduate student training. In terms of research, based on a large cohort of over ten thousand cases of genetic eye diseases, high-frequency mutant genes and mutation hotspots with characteristics of the Chinese population have been revealed, genotype-phenotype relationships have been identified, and a holographic database of biological samples and imaging data has been established, providing an important basis for the development of gene therapy drugs suitable for Chinese patients.